Both have been carried out with the participation of 25 hospitals in Spain adhering to the ENEIDA project (National Study on Intestinal Inflammatory Disease on Genetic and Environmental Determinants), an initiative of GETECCU (Spanish Working Group on Crohn's Disease and Ulcerative Colitis) and which includes data from more than 40,000 patients with Inflammatory Bowel Disease (IBD).


Both studies have focused on this more severe form of ulcerative colitis, which does not respond to the usual treatment with corticosteroids: the first, under the title "Long-term Efficacy and Safety of Cyclosporine in a Cohort of Steroids Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): a Multicenter Nationwide study "shows that the drugs used for their treatment (ciclosporin and infliximab) are equally effective for the control of the disease, with an acceptable safety profile, even though they are used sequential way.


The second, entitled "Post-operative Morbidity and Mortality of a cohort of Steroids refractory acute severe ulcerative colitis: Nationwide Multicenter study of the GETECCU ENEIDA Registry" evaluates the evolution of mortality and complications for colectomy in the last 15 years. Good news is that there is a significant and constant reduction in mortality due to this severe form of the disease during the study period, so that mortality by colectomy is practically nil in most participating centers.


These data reinforce the need to concentrate the management of these patients in centers with experience in the control of IBD, as pointed out in the "Strategic Plan on IBD" of the Catalan Society of Digestology. In this line we are working from the HUMT together with the Department of Health of the Generalitat of Catalonia and the CatSalut.